RxDoctor Payments Data

Paul McCabe, MD

Neurology · Allentown, PANPI 1114975299

Payments from drug & device makers

$31,923in general payments, 2019–2025

Across 81 payments — averaging $394.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$19K
  • Sunovion Pharmaceuticals Inc.$10K
  • UCB, Inc.$3K
  • SK Life Science, Inc.$319
  • Neurelis, Inc.$74
  • Supernus Pharmaceuticals, Inc.$50
  • plus $131 from 6 others

What the payments were for

  • Speaking & faculty fees$29,94094%
  • Travel & lodging$5552%
  • Food & beverage$1,3674%
  • Education$600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,923 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$61,754
Medicare patients
562
Services billed
716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)25$199,810
XcopriCenobamate57$91,244
TopamaxTopiramate22$60,448
BriviactBrivaracetam29$38,523
VimpatLacosamide30$34,560
FycompaPerampanel13$32,130
Trokendi XrTopiramate17$32,048
Rufinamide24$30,236
Lacosamide197$22,678
Clobazam157$19,823
NayzilamMidazolam22$17,461
Levetiracetam392$16,797
Depakote ErDivalproex Sodium13$12,129
Lamotrigine ErLamotrigine43$8,599
Oxcarbazepine53$7,786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$319$91,24457 claims
UCB, Inc.Briviact, Vimpat, Nayzilam$2,819$90,54481 claims
Eisai Inc.Fycompa$18,988$32,13013 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$50$32,04817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →